SRR1516045
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.490
- PROTEIN_SECRETION+0.360
- SPERMATOGENESIS+0.270
- TNFA_SIGNALING_VIA_NFKB+0.250
- MTORC1_SIGNALING+0.240
- ANDROGEN_RESPONSE+0.230
- MYC_TARGETS_V1+0.190
- MITOTIC_SPINDLE+0.180
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.440
- APICAL_JUNCTION-0.370
- HEDGEHOG_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- P53_PATHWAY-0.330
- NOTCH_SIGNALING-0.320
- MYOGENESIS-0.310
- ANGIOGENESIS-0.300
- COAGULATION-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X95497371.8bdb.4ede.a383.2f4daf1d1183 | — | cohortA4 | 0.784 |
| 2 | SRR2932847 | — | — | 0.782 |
| 3 | 0f095e03-de38-4be9-874c-c58893e031d9 | — | — | 0.776 |
| 4 | b25e7003-40df-4806-baee-eb8ad1c69643 | — | — | 0.760 |
| 5 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.746 |
| 6 | SRR8518162 | — | E | 0.737 |
| 7 | 06d5607b-45d7-4247-8d42-709d9d292530 | — | — | 0.735 |
| 8 | 63f6d3e9-3f4b-44fa-8e48-980c70b7e4f1 | — | — | 0.734 |
| 9 | SRR10899995 | — | — | 0.731 |
| 10 | DRR168535 | — | — | 0.731 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |